Evidence map›Paper›PMID 39404788›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Using a novel PSMA-PET and PSA-based model to enhance the diagnostic accuracy for clinically significant prostate cancer and avoid unnecessary biopsy in men with PI-RADS ≤ 3 MRI.

Yujia Li, Jian Li, Jinhui Yang, Ling Xiao, Ming Zhou, Yi Cai, Axel Rominger, Kuangyu Shi, Robert Seifert, Xiaomei Gao and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026
    Article
  2. The value of [Quantitative imaging in medicine and surgery · 2026
    Article
  3. Article
  4. Article
  5. Overdiagnosis and Overtreatment in Prostate Cancer.Diseases (Basel, Switzerland) · 2025
    Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yujia Li *Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jian Li *Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jinhui YangDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Ling XiaoDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Ming ZhouDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yi CaiDepartment of Urology, Disorders of Prostate Cancer Multidisciplinary Team, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Axel RomingerDepartment of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland.
Kuangyu ShiDepartment of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland.
Robert SeifertDepartment of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland.
Xiaomei GaoDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China. lswindy_2012@163.com.
Yongxiang TangDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China. 405035@csu.edu.cn.
Shuo HuDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China. hushuo2018@163.com.ORCID 0000-0003-0998-8943

Funding

China Postdoctoral Science Foundation 2022M23561Clinical Research Foundation of the National Clinical Research Center for Geriatric Diseases (XIANGYA) 2023LNJJ16Hunan Provincial Science Found for Distinguished Younger Scholars 2024JJ2094Innovative Construction Foundation of Hunan Province 2021SK4001Key Program of Ministray of Industry and Information Technology of China CEIEC-2022-ZM02-0219National Natural Science Foundation of China 81801740National Natural Science Foundation of China 82272045National Natural Science Foundation of China 82273121Natural Science Foundation of Hunan Province 2022JJ20096Natural Science Foundation of Hunan Province 2023JJ30939Science and Technology Innovation Program of Hunan Province 2021RC4056The National Key clinical specialty Major Scientific Research Project of Hunan Province Z2023004
6 · The paper itself

Abstract

introductionThe diagnostic evaluation of men with suspected prostate cancer (PCa) yet inconclusive MRI (PI-RADS ≤ 3) presents a common clinical challenge. [ MATERIALS AND

methodsThis study retrospective included 151 men with clinical suspicion of PCa and PI-RADS ≤ 3 MRI. All men underwent [

resultsIn this PI-RADS ≤ 3 cohort, areas-under-the-curve (AUCs) for detecting csPCa were 0.796 (95%CI, 0.738-0.853), 0.851 (95%CI, 0.783-0.918) and 0.806 (95%CI, 0.742-0.870) for PRIMARY-score, SUVmax and routine clinical PSMA-PET assessment, respectively. The diagnostic model comprising PRIMARY-score, SUVmax and serum free PSA/total PSA (fPSA/tPSA) achieved a significantly higher AUC of 0.906 (95%CI, 0.851-0.961) compared to strategies based on PRIMARY-score or SUVmax (P < 0.05) and markedly superior to conventional strategies typically based on PSA density (P < 0.001). The average fivefold cross-validated AUC with 1000 iterations was 0.878 (95%CI, 0.820-0.954). Theoretically, using a threshold of 21.6%, the model could have prevented 78% of unnecessary biopsies while missing only 7.8% of csPCa cases in this cohort.

conclusionsA novel diagnostic model incorporating PSMA-PET derived metrics-PRIMARY-score and SUVmax-along with serum fPSA/tPSA, has been developed and validated. The integrated model may assist clinical decision-making with enhanced diagnostic accuracy over the individual conventional metrics. It has great potential to reduce unnecessary biopsies for men with PI-RADS ≤ 3 MRI results and warrants further prospective and external evaluations.

Indexed as

Antigens, SurfaceEdetic AcidGlutamate Carboxypeptidase IIMagnetic Resonance ImagingPositron Emission Tomography Computed TomographyProstate-Specific AntigenProstatic NeoplasmsUnnecessary ProceduresAgedGallium IsotopesGallium RadioisotopesHumansMaleMiddle AgedRetrospective StudiesAntigens, SurfaceEdetic AcidFOLH1 protein, humangallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesGlutamate Carboxypeptidase IIProstate-Specific AntigenMpMRIPETPI-RADSPRIMARY-scoreProstate cancerPSMA

Identifiers

PMID39404788

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.